Literature DB >> 26036595

Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: A binary choice experiment.

Wendy Hopmans1, Laura Zwaan2, Suresh Senan3, Ineke van der Wulp4, Olga C Damman4, Koen J Hartemink5, Egbert F Smit6, Danielle R M Timmermans4.   

Abstract

BACKGROUND AND
PURPOSE: Surgery is the standard of care in stage I non-small cell lung cancer (NSCLC), but stereotactic ablative radiotherapy (SABR) is increasingly used to treat patients at high-risk for surgical complications. We studied which patient- and clinician-related characteristics influenced treatment recommendations.
MATERIAL AND METHODS: A binary choice experiment with hypothetical cases was conducted. Cases varied on five patient-related characteristics: patient age, Chronic Obstructive Pulmonary Disease Global Initiative for Chronic Obstructive Lung Disease (COPD GOLD) score, Charlson co-morbidity index, World Health Organization performance status (WHO-PS) and patient treatment preference (surgery/SABR). Clinician characteristics were recorded. Responses were analyzed using generalized linear mixed models.
RESULTS: 126 clinicians completed the survey. All patient-related characteristics, the clinician speciality, and whether clinicians considered outcomes of surgery comparable to SABR, significantly influenced treatment recommendations. Pulmonologists were most influenced by WHO-PS and comorbidity, whereas comorbidity and age had greatest influence on radiation oncologists and surgeons. Clinicians were less influenced by stated patient preference and COPD GOLD score. Limited consistency was observed in treatment recommendations.
CONCLUSIONS: This study suggests that more efforts are needed to develop uniform approaches for making treatment recommendations, and also to incorporate patient preferences when making treatment decisions for stage I NSCLC.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; Practice variation; Stereotactic ablative radiotherapy; Surgery; Thoracic oncologists

Mesh:

Year:  2015        PMID: 26036595     DOI: 10.1016/j.radonc.2015.05.006

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Surgery versus SABR for early stage non-small cell lung cancer: the moving target of equipoise.

Authors:  Houda Bahig; Hanbo Chen; Alexander V Louie
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

2.  Treatment recommendations by clinicians in stage I non-small cell lung cancer: better work-up leads to less discussion.

Authors:  Jo Raskin; Annelies Janssens; Jan P Van Meerbeeck
Journal:  Ann Transl Med       Date:  2017-11

3.  Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter?

Authors:  Helen A Powell; David R Baldwin
Journal:  Ann Transl Med       Date:  2017-10

4.  Thoracic surgeon and patient focus groups on decision-making in early-stage lung cancer surgery.

Authors:  Rebecca M Schwartz; Ksenia Gorbenko; Samantha M Kerath; Raja Flores; Sheila Ross; Tonya N Taylor; Emanuela Taioli; Claudia Henschke
Journal:  Future Oncol       Date:  2017-12-12       Impact factor: 3.404

5.  The Value of Hope: Patients' and Physicians' Preferences for Survival in Advanced Non-Small Cell Lung Cancer.

Authors:  Brett Hauber; John R Penrod; David Gebben; Lina Musallam
Journal:  Patient Prefer Adherence       Date:  2020-10-30       Impact factor: 2.711

Review 6.  SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?

Authors:  Hanbo Chen; Alexander V Louie
Journal:  Curr Treat Options Oncol       Date:  2016-06

7.  The use of PROMs and shared decision-making in medical encounters with patients: An opportunity to deliver value-based health care to patients.

Authors:  Olga C Damman; Anant Jani; Brigit A de Jong; Annemarie Becker; Margot J Metz; Martine C de Bruijne; Danielle R Timmermans; Martina C Cornel; Dirk T Ubbink; Marije van der Steen; Muir Gray; Carla van El
Journal:  J Eval Clin Pract       Date:  2019-12-15       Impact factor: 2.431

8.  Questionnaire survey comparing surgery and stereotactic body radiotherapy for lung cancer: lessons from patients with experience of both modalities.

Authors:  Atsuya Takeda; Naoko Sanuki; Yuichiro Tsurugai; Masataka Taguri; Nobuyuki Horita; Yu Hara; Takahisa Eriguchi; Takeshi Akiba; Akitomo Sugawara; Etsuo Kunieda; Takeshi Kaneko
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

9.  A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study.

Authors:  Wendy Hopmans; Olga C Damman; Suresh Senan; Koen J Hartemink; Egbert F Smit; Danielle R M Timmermans
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

Review 10.  Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate.

Authors:  Gail Wan Ying Chua; Kevin Lee Min Chua
Journal:  Thorac Cancer       Date:  2019-08-06       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.